<SEC-DOCUMENT>0001140361-25-020062.txt : 20250521
<SEC-HEADER>0001140361-25-020062.hdr.sgml : 20250521
<ACCEPTANCE-DATETIME>20250521165638
ACCESSION NUMBER:		0001140361-25-020062
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250521
FILED AS OF DATE:		20250521
DATE AS OF CHANGE:		20250521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CREDICORP LTD
		CENTRAL INDEX KEY:			0001001290
		STANDARD INDUSTRIAL CLASSIFICATION:	COMMERCIAL BANKS, NEC [6029]
		ORGANIZATION NAME:           	02 Finance
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14014
		FILM NUMBER:		25973770

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		STREET 2:		P.O. BOX HM 666,
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM CX
		BUSINESS PHONE:		5113135140

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		STREET 2:		P.O. BOX HM 666,
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM CX
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ef20049504_6k.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial; font-size: 9pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Report of Foreign Private Issuer</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to Rule 13a-16 or 15d-16 under the</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Securities Exchange Act of 1934</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the month of May 2025</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Commission File Number: 001-14014</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 24pt; font-weight: bold;">CREDICORP LTD.</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Of our subsidiary</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Banco de Credito del Peru:</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Calle Centenario 156</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">La Molina 15026</div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Lima, Peru</div>
      <div style="text-align: center; color: #000000; font-family: 'Times New Roman', serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;">&#160;</font><font style="font-family: 'Times New Roman';">(Address of principal
          executive office)</font></div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Form 20-F &#9746; Form 40-F &#9744;</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font></div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><img src="image00001.jpg">
        <div><br>
        </div>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">May 21, 2025</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Securities and Exchange Commission - SEC</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Re.: MATERIAL EVENT</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Dear Sirs:</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Credicorp Ltd. (the &#8220;Company&#8221;) notifies you as a Material Event that, in response to the Official Letter N.&#176; 2302-2025-SMV/11.1 issued by the Peruvian Superintendency
        of Securities Market (SMV), the Company has sent on May 20, 2025, the attached response (translated into English from the original in Spanish). Such response was published as a Material Event in the Peruvian market.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The information in this Form 6-K (including any exhibits hereto) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934
        (the &#8216;Exchange Act&#8217;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Sincerely,</div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">/s/ <u>Guillermo Morales</u></div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Authorized Representative</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Credicorp Ltd.</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">SIGNATURE</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="text-indent: 29.7pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</div>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <table cellspacing="0" cellpadding="0" border="0" id="zd006996de4634c2f8a8f0a4c25bcc749" style="font-family: Arial; font-size: 9pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1"><br>
            </td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">
              <div>
                <div>
                  <div>
                    <div>Date: May 21, 2025</div>
                  </div>
                </div>
              </div>
            </td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="vertical-align: top;" colspan="2">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">CREDICORP LTD.</div>
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">(Registrant)</div>
            </td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 33.41%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">By:</div>
            </td>
            <td style="width: 33.41%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0);">/s/ Guillermo Morales</div>
            </td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 33.41%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Guillermo Morales</div>
            </td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          </tr>
          <tr>
            <td colspan="1" style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 45%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 5%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
            <td style="width: 33.41%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">
              <div style="color: rgb(0, 0, 0); font-weight: bold;">Authorized Representative</div>
            </td>
            <td style="width: 11.69%; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</td>
          </tr>

      </table>
      <div><font style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"> </font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
        </font></div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
  <font style="font-family: 'Times New Roman'; font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ef20049504_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, LLC
         Document created using Broadridge PROfile 25.3.2.5298
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: Arial; font-size: 9pt; text-align: left; color: #000000;">
  <font style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right; font-weight: normal;"><font style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;">Exhibit 99.1</font><font style="font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </font></div>
    <div style="font-weight: bold;"> <font style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </font>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Lima, May 20, 2025</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Peruvian Superintendency of the Securities Market</div>
      <div style="text-align: justify; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Present</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">. &#8211;</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z7b8a71a3d2f34072a16a7592eabe9f59" style="font-family: Arial; font-size: 9pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 54pt;">
                <div style="text-align: left;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Reference:</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">a) Official Letter No. 2302-2025-SMV/11.1</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc08da97104ab4863b19ee28970f2c803" style="font-family: Arial; font-size: 9pt; width: 100%;">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 54pt;"><br>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
                  <div style="font-weight: normal;">b) File No. 2025017716</div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Dear Sirs,</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">We hereby respond to the referenced Official Letter (the &#8220;<u>Letter</u>&#8221;), through which the General Office of Conduct Supervision has requested
        information regarding the administration of saline solution at <font style="font-weight: bold;">SANNA Cl&#237;nica San Borja</font> and <font style="font-weight: bold;">SANNA Cl&#237;nica S&#225;nchez Ferrer</font>, Trujillo branch (part of the SANNA Clinic
        Network) (hereinafter, the &#8220;<u>Administration of Saline Solution</u>&#8221;), operated by La Esperanza del Per&#250; S.A. and Cl&#237;nica S&#225;nchez Ferrer S.A., respectively, companies that are part of the Credicorp Ltd. Economic Group.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Below, we address the information request in the same order as presented in the Letter:</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z50e72190bd394fb8a4a18f9e3af1a103">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial,sans-serif; font-size: 10pt; font-weight: bold;"><font style="font-family: 'Times New Roman';"><u>Question No. 1</u>: Explain why your company has not yet disclosed, as a material event, all documentation
                  related to the events at SANNA Cl&#237;nica San Borja and SANNA Cl&#237;nica S&#225;nchez Ferrer.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: normal;"><u>Response</u>: The mentioned clinics are subsidiaries of Pac&#237;fico S.A. Entidad
          Prestadora de Salud, which in turn is a subsidiary of Pac&#237;fico Compa&#241;&#237;a de Seguros y Reaseguros S.A., a company whose shares are registered in the Public Registry of the Securities Market. Since these unfortunate events occurred, SANNA has issued
          two public statements explaining what happened. Additionally, the events have received extensive media coverage. Finally, and no less importantly, the manufacturer of the aforementioned saline solution (Medifarma) has publicly acknowledged
          responsibility for its defective product.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2e24e989871c42c1a447b594f74ae770">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Question No. 2</u>: Disclose all information related to the administration of defective saline solution to
                  various patients in the SANNA Clinic Network.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: On March 18, 2025, SANNA / Cl&#237;nica San Borja received 720 bottles from batch 2123624 of 0.9% saline solution in 1000cc presentation for intravenous use (hereinafter, &#8220;defective saline from Medifarma&#8221;). That same day, the first case
          occurred: a 26-year-old female patient was admitted to the Adult Emergency Area at 9:30 p.m. with an acute upper respiratory condition with fever. She was taking medications that affected the central nervous system, and reported allergies to
          Paracetamol and NSAIDs. Intravenous hydration with the defective saline from Medifarma was prescribed. By 12:30 a.m. on March 19, 2025, she experienced altered consciousness and seizures and was diagnosed with severe hypernatremia. Despite
          multidisciplinary management in the ICU, she unfortunately progressed to brain death and passed away on April 18, 2025.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">The second severe case occurred on March 20, 2025, involving a 46-year-old female patient admitted to the Operating Room for
        elective surgery under general anesthesia. In the postoperative period on March 21, 2025, at 3:00 a.m., she developed severe hypernatremia (199 mmol/L) and seizures after receiving the defective saline from Medifarma. She required ICU care, and
        despite medical interventions, the patient's condition deteriorated, and unfortunately, she developed brain death and passed away on April 17, 2025.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">The third severe case occurred on March 20, 2025, involving a one-year-old female infant admitted to Pediatric Emergency at
        9:00 p.m. with acute diarrhea, poor oral tolerance, and fever. She was hospitalized and received 480cc of defective saline from Medifarma intravenously. She experienced seizures during hospitalization and was transferred to the ICU, where she
        developed severe hypernatremia. On March 21, 2025, her parents requested her transfer to the Guillermo Almenara Irigoyen National Hospital, which was carried out the same day. Unfortunately, she later passed away at that institution.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Simultaneously, between March 20 and 21, 2025, four patients reported burning-type pain associated with the infusion of the
        defective saline from Medifarma, administered without any other medication. A cause-effect relationship was identified, prompting a meeting of the institution&#8217;s Pharmacovigilance Committee on March 21, 2025, at 2:00 p.m., where the following
        actions were decided:</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc767cc7b4750457591cdf6af284027df">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Remove from the clinic&#8217;s storage areas all 0.9% saline solution in 1000cc presentation for intravenous infusion from any Medifarma batch and quarantine them in the product review area.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zee6f6115f84341d6aae5f18495cd9c27">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Replace Medifarma saline solution being administered to patients with another brand.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf075f169dfce4d4a91ce03187800dbc7">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Report on the four suspected adverse drug reactions to DIGEMID via the Vigiflow system.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z971714b29ea348dc828f2fce6da971ca">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Notify Medifarma of the incidents and request a review of their quality control for the affected batch.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3853b4d90d684a6fa39d148ec05e8c0f">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Conduct random sampling and analysis of Medifarma&#8217;s 0.9% saline bottles from various batches in circulation between March 18 and 21.</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">As a result of these measures, 358 bottles of Medifarma&#8217;s saline solution for intravenous infusion were quarantined. The
        distribution of the quarantined bottles was as follows: (i) thirty (30) bottles were sent to the Hypatia S.A. laboratory for analysis, (ii) forty-eight (48) bottles were collected by the General Directorate of Medicines, Supplies and Drugs &#8211;
        DIGEMID for the corresponding purposes, and (iii) the remaining two hundred eighty (280) bottles were ultimately retrieved by the Medifarma laboratory.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">The results of the analyses conducted by Hypatia S.A. revealed severe irregularities in the composition of the product:
        elevated concentrations were detected in batch 2123624-1 exceeding 600%, and reduced concentrations in batch 2123624-4 below 60%. These results demonstrate non-compliance with the standards required by national and international regulations for the
        product to be considered suitable for human use.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">On March 21, 2025, following the conclusion of the Pharmacovigilance Committee meeting, the Corporate Medical Director of the
        SANNA Clinic Network informed all of the suspicions regarding the product&#8217;s quality. Additionally, the adverse events experienced by our patients were reported to DIGEMID, and Medifarma was informed of the incidents, with an urgent request for a
        review of their quality control processes.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Following the alert issued by <font style="font-weight: bold;">SANNA Cl&#237;nica San Borja</font> through its Medical Director on
        March 21, 2025, and the subsequent alert from DIGEMID on March 24, 2025, <font style="font-weight: bold;">SANNA Cl&#237;nica S&#225;nchez Ferrer</font> conducted a retrospective investigation into the severe hypernatremia cases treated at its facility. The
        findings are detailed below:</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z191235de394a46be9fb676d98b84570d">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;">SANNA Cl&#237;nica S&#225;nchez Ferrer</font><font style="font-weight: normal; font-family: 'Times New Roman';"> received
                  1,008 bottles of the defective saline solution batch 2123624 from Medifarma on February 10, 2025. As of March 21, 2025, only five (5) bottles remained available, of which three (3) were sent to the company Hypatia S.A. on March 25, 2025,
                  for the corresponding analysis. The remaining two (2) bottles were handed over to the Public Prosecutor&#8217;s Office and GERESA.</font></div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9414381537b146b084fbfbfa74b1f730">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>During this period, two patients were identified who, among other diagnoses, developed severe hypernatremia during their hospitalizations. These cases were attributed to causes other than sodium overload from defective saline, given that
                multiple patients simultaneously received saline solution from the same batch without presenting any symptoms or signs associated with that diagnosis during their medical care.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7b524c2638fc43c08f86524ed6bacde3">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>The first case involved a 72-year-old female patient with multiple chronic conditions under appropriate treatment and control. She was admitted on February 20, 2025, due to an acute condition that required intravenous hydration as part
                of her treatment. During her hospitalization, she developed a case of severe hypernatremia (196 mmol/L) and was transferred to the ICU. Despite the efforts made by the multidisciplinary team in managing the diagnosis, the patient&#8217;s
                condition deteriorated, and she unfortunately passed away on February 28, 2025.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaf1662d206cd429fbdff4604c5a7e650">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>The second case involved a 91-year-old male patient with multiple comorbidities, who was chronically bedridden and had a history of several previous hospitalizations. He was admitted on March 4, 2025, due to an acute abdominal surgical
                condition. He underwent emergency surgery and was transferred to the ICU for multidisciplinary management. From the time of admission, he received intravenous hydration with saline solution. On March 6, 2025, he developed severe
                hypernatremia (197 mmol/L). Despite medical care, his condition deteriorated, and he unfortunately passed away on March 11, 2025.</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">In response to these events, SANNA took the following actions:</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z262fb1c3df944f7aac64b30088ba0a7e">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Contacted the families of patients affected by the defective saline to inform them of the events and the patients&#8217; conditions.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze5f7bc062dea48a2989b6d76eadc0c4d">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Psychological support was offered to the families of the patients affected by Medifarma&#8217;s saline solution, and the waiver and reimbursement of the patients&#8217; medical expenses were communicated.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z072838bda5ca4c7dbadabb7b5101b15b">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>For non-critical patients affected by Medifarma&#8217;s defective saline, each clinic conducted daily symptom monitoring and provided free medical care and tests. To date, all of these patients have been discharged.</div>
            </td>
          </tr>

      </table>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6c053f9b198d4d5cbaf89ed127c34593">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>Finally, active cooperation was provided to administrative and criminal authorities by supplying all the information required within the framework of the corresponding investigations.</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za5903d11691e4a5cad757ca655e96043">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Question No. 3</u>: Confirm and/or clarify all information about the legal proceedings initiated by MINSA
                  against the SANNA Clinic Network.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: To date, none of the clinics within the SANNA Clinic Network has been notified of any legal proceedings initiated by the Ministry of Health (MINSA) in relation of the Administration of Saline Solution.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Nevertheless, we are aware, through reports in the media, that as of today, there are three (3) criminal investigations related
        to the administration of Medifarma&#8217;s saline solution, in which representatives and/or medical personnel from <font style="font-weight: bold;">SANNA Cl&#237;nica San Borja&#160;and SANNA Cl&#237;nica S&#225;nchez Ferrer</font> are or could be involved.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za401f95a049648fb9e75c20b1b873149">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">(i)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>A first criminal investigation, related to the Administration of Saline Solution at <font style="font-weight: bold;">SANNA Cl&#237;nica S&#225;nchez Ferrer</font>, was initiated by the First Provincial Corporate Criminal Prosecutor&#8217;s Office of
                Trujillo and later transferred to the Second Provincial Corporate Criminal Prosecutor&#8217;s Office of Santa Anita, in the Lima East District. A jurisdictional dispute is currently pending resolution to determine which prosecutor&#8217;s office is
                competent to handle the investigation.</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb40ab8c69e9346e5b9ef376a0d2c4ddc">

          <tr>
            <td style="width: 18pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">(ii)</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;">
              <div>The other two criminal investigations are related to the Administration of Saline Solution at <font style="font-weight: bold;">SANNA Cl&#237;nica San Borja</font> and were initiated by the Office of the Attorney General of the Ministry of
                Health or by relatives of affected patients. These investigations are in the preliminary stage and are being handled by the Third Office of the Second Provincial Criminal Prosecutor&#8217;s Office of Santa Anita and the Third Office of the Second
                Criminal Prosecutor&#8217;s Office of Miraflores, Surquillo, and San Borja.</div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2d23a3d46d9646a8bbedfdcb17386286">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial,sans-serif; font-size: 10pt; font-weight: bold;"><font style="font-family: 'Times New Roman';"><u>Question No. 4</u>: Report whether any administrative proceedings have been initiated by Peruvian State
                  authorities against any of the clinics within the SANNA Clinic Network, which are part of your economic group, or against their respective officials</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: As of today, the National Superintendency of Health &#8211; SUSALUD is the only entity that has initiated administrative sanctioning procedures (PAS) related to the events involving the administration of defective saline solution at <font style="font-weight: bold;">SANNA Cl&#237;nica S&#225;nchez Ferrer</font> and <font style="font-weight: bold;">SANNA Cl&#237;nica San Borja.</font></font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">A total of four (4) PAS have been initiated, either ex officio or based on third-party complaints: one (1) against SANNA
        Cl&#237;nica S&#225;nchez Ferrer and the remaining three (3) against SANNA Cl&#237;nica San Borja.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">As of now, all PAS are still in progress. On May 7, 2025, responses were submitted to the alleged violations attributed to
        SANNA Cl&#237;nica S&#225;nchez Ferrer and SANNA Cl&#237;nica San Borja, requesting that the complaints be declared unfounded and that the procedures be closed.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">SUSALUD, through its Office for the Protection of Health Rights (IPROT), has also initiated an investigation against SANNA
        Cl&#237;nica San Borja regarding a patient who developed thrombophlebitis following a surgical procedure. This case is currently under review, and all information requested by the authority has been provided.</div>
      <div style="margin-bottom: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 9pt; margin-bottom: 9pt;">
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zcb2970647ae54966beebd6760671e230">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial,sans-serif; font-size: 10pt; font-weight: bold;"><font style="font-family: 'Times New Roman';"><u>Question No. 5</u>: Provide detailed information on all decisions made by the governing bodies of your company or
                  of the companies within your economic group in relation to the serious events mentioned. If no decisions have been made, please report this situation and indicate the reasons.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: The Board of Directors and the management teams of each clinic (S&#225;nchez Ferrer and San Borja) have closely and continuously monitored the situation arising from these unfortunate events. From the outset, they expressed their concern
          and commitment to ensuring that patients and their families received appropriate care and, where applicable, that the situation be compensated.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">In addition, necessary measures have been taken to prevent such an incident from recurring. Among these, additional internal
        controls have been implemented. Furthermore, the Peruvian Society of Medical Auditing (SPAM) was commissioned to conduct a specialized audit of the procedures followed by the medical staff in the reported cases, the results of which were
        satisfactory.</div>
      <div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zed492db86c2a4c09b6110ba409b4232d">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">6.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Question No. 6</u>: Report everything related to the economic/financial impact caused by the aforementioned
                  events and their consequences on your organization and/or the companies within your economic group, as well as the measurement of such impact to date.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: We deeply regret the deaths that have occurred and express our solidarity with the victims' families. However, as of today, the economic or financial impact of these events is not expected to be significant for our company or its
          economic group. This is based on the fact that responsibility for the consequences of this defective product lies with the manufacturer (Medifarma), and not with our institution.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9469104bb56144df8143f1246890240e">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">7.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Question No. 7</u>: Indicate all information related to the measurement of reputational impact on your company
                  and the companies within your economic group.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Response</u></font><font style="font-weight: normal; font-family: 'Times New Roman';">: In this regard, we are currently conducting a brand study in order to assess the reputational impact that these events may be generating on our SANNA Clinic Network. As a preliminary observation, we can report that, to date, there has
          been an increase in mentions and comments on social media and in the press, many of which reflect a negative perception of our clinic.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: Arial; font-size: 9pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4d9e9af43deb46bfbd19785bebda8266">

          <tr>
            <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">8.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div style="font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: normal;"><font style="font-weight: bold;"><u>Question No. 8</u></font>: Provide any additional relevant information
                  regarding the matters addressed in this Letter.</font></div>
            </td>
          </tr>

      </table>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; margin-left: 18pt; font-family: Arial, sans-serif; font-size: 10pt;"><font style="font-family: 'Times New Roman'; font-weight: normal;"><font style="font-weight: bold;"><u>Response</u></font>:&#160;All relevant information
          has been provided in the previous sections.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: Arial, sans-serif; font-size: 11pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">With nothing further, we remain at your disposal.</font></div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Sincerely,</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CREDICORP LTD.</div>
      <div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"><br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Guillermo Morales Valent&#237;n</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Authorized Representative</div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;"> <br>
      </div>
      <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
  <font style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  N 0@# 2(  A$! Q$!_\0
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M6L+[&95D(0GD*6,@!./2M6?XY^.O"DD<OQ"^'TMKIS,%:YM=RA?Q8LI/MN%
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M35?-W[,]G>^*O'_B_P")%];M;VVH.]O:!NX+ G'KM"(N?7/I7TC0!\W>"/\
MD\;Q?_UXM_Z#!7TC7S=X(_Y/&\7_ /7BW_H,%?2- 'S)J-C'\1_VKKC3M:7S
M](\/6P=+9^4<J$/(]"\@)]0H%?32J%4*H 4#  ' KYD^(5Q+\)_VB;?QG=PR
M/X=UR+R+F5%)\L[55A]045\=QG%?1^C:MI^MZ?%?:1>07MI*-R2P.&4_E_*@
M"[15-M5T]=3CTYKZV&H2*72V\U?,91U(7.<"KE '):IHFIZWJB'4'CAT]#\L
M:/DX_P 3ZUTT5G;Q68M4B06X7;LQP17)>(+*_P!$NQJ>F32R6P.9(68L%]>/
M[O\ *M2'Q9IKZ9]J>4)(!S!GY\^@]?K0!0AT#4-'U<W&C.CVK_>AD?''I_@:
MZY22H+#!QR/2N'TF'4/$NH&^NY9;?3U.%C1BN[V']3_D=PJA5"KP ,"@#P?]
MLW_DE%I_V%(O_1<E>GVWB'2?#7@'2]0UV_M[*TCL827E<#/[L< =2?8<UYA^
MV;_R2BT_["D7_HN2K_Q=^'0\?_!W2C91@ZWIME%<69 YD_=KNB_X$!Q[@4 <
MS^RA:3:CXE\>>*[>V>UT;4[LK:(5P&_>.YQ_NA@/J2*^D*\D_9J\<6OBSX?V
M]CY4-KJFCJMK=6T:!!@?=D"CINP<_P"T&KUN@#YQL?\ D]74?^P</_2:.M3]
MK#Q;HB> +CPPD\-YKU_-"(;6([Y(MKABQ Z=-H[G=]:R['_D]74?^P</_2:.
MO7-+^&7A'3?%UYXFMM'A.LW4IF,\A+B-SU9%/"DGG(&>30!8^%>D7>@_#?PW
MI>H@K>6MC%'*I_@;;ROX=/PHKJJ* "L'QGX0T/QGI)T[Q'817EOG<A;(>-O[
MRL.5/TK>HH \!D_9DT*.1UTWQ+X@L[1SDP+*I'YX'ZUWOPP^$WASX=37%SHQ
MO)[ZXC\J6XNIMQ9<YQ@ *.0.V?>O0:* "N ^'/PSL_ _B+Q)JUIJ%S=2:W-Y
MTD<J*!$=[M@8Z_?[^E=_10!QGQ5^'NE_$?PXNE:J\D#Q2B:"YB +Q-WQGL1D
M$?3TK=\)Z3-H7AVPTNXU";47M(A$+F90'=1]W=CN!@9[XK6HH YWXA>$K/QQ
MX1OM U*6:&WN@O[R$C<C*P8$9XZ@5XK#^RUID";(?%NM1IUVHJ@5]&44 <?\
M+? \7P_\.2:1!J-UJ*O<-<>=<XW#(48X[?+^M=7=0)=6LUO,"8Y4,; '&01@
MU+10!\YK^ROHT,LC6?BC6+=&/"JJ9QV!(QFM30_V9/"=K?)<ZUJ&K:SL.1%/
M*$0_7:-Q_,5[Q10!7TZQM=-L8++3[>*VM($"10Q*%5%'8 58HHH X#1_AG9Z
M9\5M5\=1ZA<27>H0F%K5D7RT!"#(/7^ ?G7?T44 9WB'0],\1:3-INN64-[8
MS#YXI5R/8CN".Q'->+WG[,WAQ;J231-=UW2HG/,,4P91[ D9_,FO>:* /+?A
MS\$?#/@;6DUFTFU&^U9%95N+J;[NX8.%4 <@]\UZE110 C ,I# $$8(/>N1G
M\%6SZP)T?99'YFA'7/H/:NOHH ;%&D4:QQ*$11A5 P *=110!Q7Q9\ 6OQ'\
M,Q:-?7L]E%'<K<B2%0Q)56&.>WS?I76:7:+I^FVEFC%UMX4A#'J0J@9_2K-%
M 'FVD_">QT3XH77C+1-3NK%KS=]JT]$4PS;A\WN,MAO8UZ3110!P,/PTLXOB
@[/X^&H7!O)H! ;78OE@>6J9SU_AS7?444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
